Tango Therapeutics, Inc. (TNGX) Stock
NASDAQ · TNGX
24.43
Fundamentals
Market cap
$4.20B
Price / Earnings ratio
-33.6x
Price / Sales ratio
77.2x
Price / Book ratio
4.0x
Return on assets
-33.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Zacks Investment Research
Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?
NeutralTNGXSeptember 10, 2026
Zacks Investment ResearchNeutral
Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?
TNGX

Zacks Investment Research
TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses
NeutralTNGXAugust 12, 2026
Zacks Investment ResearchNeutral
TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses
TNGX

Zacks Investment Research
4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
NeutralTNGXAugust 3, 2026
Zacks Investment ResearchNeutral
4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
TNGX

Zacks Investment Research
How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48%
NeutralTNGXJuly 22, 2026
Zacks Investment ResearchNeutral
How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48%
TNGX
Technicals
OscillatorsBuy5 Indicators
Moving AveragesStrong Buy12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy4
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
75M49M25M0
Debt & Balance Sheet
Total assets
Total liabilities
2025
478M316M158M0
Revenue to Profit
2025$62.4M
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-101.6M
Net incomeEarnings
EPS forecast
Actual EPS
$-0.30
Q1FY26
$-0.31
Q2FY26
The market is expecting earnings per share of -$0.31 for this quarter. The company has not yet shared when it is announcing earnings.
% positive news of 10 articles
published over the past 14 days
Latest news

Zacks Investment Research
Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?
NeutralTNGXSeptember 10, 2026
Zacks Investment ResearchNeutral
Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?
TNGX

Zacks Investment Research
TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses
NeutralTNGXAugust 12, 2026
Zacks Investment ResearchNeutral
TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses
TNGX

Zacks Investment Research
4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
NeutralTNGXAugust 3, 2026
Zacks Investment ResearchNeutral
4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
TNGX

Zacks Investment Research
How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48%
NeutralTNGXJuly 22, 2026
Zacks Investment ResearchNeutral
How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48%
TNGX

Zacks Investment Research
Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026?
NeutralTNGXJuly 2, 2026
Zacks Investment ResearchNeutral
Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026?
TNGX

Zacks Investment Research
Tango Therapeutics Rides a New Precision Oncology Trend in 2026
NeutralTNGXJuly 2, 2026
Zacks Investment ResearchNeutral
Tango Therapeutics Rides a New Precision Oncology Trend in 2026
TNGX

Zacks Investment Research
TNGX Stock Outlook Hinges on Vopimetostat and Key 2026 Catalysts
NeutralTNGXJuly 2, 2026
Zacks Investment ResearchNeutral
TNGX Stock Outlook Hinges on Vopimetostat and Key 2026 Catalysts
TNGX

Zacks Investment Research
TNGX Stock Jumps 53% on Early Pancreatic Cancer Study Results
NeutralTNGXJune 9, 2026
Zacks Investment ResearchNeutral
TNGX Stock Jumps 53% on Early Pancreatic Cancer Study Results
TNGX

Stocktwits
TNGX Stock Hits All-Time High – Wolfe Research Calls Tango Therapeutic’s Pancreatic Cancer Trial Data ‘Groundbreaking’
NeutralTNGXJune 8, 2026
StocktwitsNeutral
TNGX Stock Hits All-Time High – Wolfe Research Calls Tango Therapeutic’s Pancreatic Cancer Trial Data ‘Groundbreaking’
TNGX

Investors Business Daily
Tango Skyrockets 47% On Eye-Popping Pancreatic Cancer Results
NeutralTNGXJune 8, 2026
Investors Business DailyNeutral
Tango Skyrockets 47% On Eye-Popping Pancreatic Cancer Results
TNGX
About Tango Therapeutics, Inc.
No description available.
SectorHealthcare
IndustryBiotechnology
Employees137
CEODr. Malte Peters M.D.
IPO DateSep 3, 2020
HeadquartersBoston, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Malte Peters M.D. | President, CEO & Director | 1962 |
| Dr. Barbara L. Weber M.D. | Executive Officer | 1957 |
| Dr. Adam S. Crystal M.D., Ph.D. | President of Research & Development | 1977 |
| Prof. Alan Ashworth FRS, Ph.D. | Founder & Member of Scientific Advisory Board | 1961 |
| Dr. William G. Kaelin Jr., M.D. | Founder & Member of Scientific Advisory Board | 1958 |
| Dr. Antoni Ribas M.D., Ph.D. | Founder & Member of Scientific Advisory Board | 1967 |
| Mr. Matthew Gall M.B.A. | Chief Financial Officer | 1977 |
| Mr. Jannik N. Andersen Ph.D. | Chief Scientific Officer | — |
| Ms. Elizabeth Pingpank Hickin | VP of IR & Corporate Communications | — |
| Ms. Julie Fogarty | Senior VP, General Counsel & Corporate Secretary | — |
Fundamentals
Valuation
Market cap$4.20B
Price-to-sales ratio77.18
Price-to-book value4.05
Price-earnings ratio-33.60
Return on Equity-42.00%
Return on Sales-188.00%
Return on Assets-33.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-0.85
Income Statement
Average volume2,808,502
EBITDA$-101.22M
1 year high (52w)$34.39
1 year low (52w)$6.69
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsBuy5 Indicators
Moving AveragesStrong Buy12 Indicators
What the experts say
5 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$47.00
Est return
88.68%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +7.5 | -2.4 | -19.7 | +9.4 | ||||||||
| 2022 | -22.0 | -0.7 | -20.0 | -1.7 | -10.0 | -30.5 | -13.9 | +7.6 | -15.0 | +135.8 | -4.1 | -6.2 |
| 2023 | -9.7 | -23.6 | -24.0 | -22.0 | -18.9 | +24.3 | +7.3 | +99.1 | +57.3 | -25.3 | -7.4 | +27.6 |
| 2024 | +17.7 | -9.4 | -30.6 | +0.8 | -4.9 | +22.6 | +9.4 | +25.2 | -29.6 | -25.3 | -23.5 | -20.6 |
| 2025 | -4.8 | -28.9 | -27.9 | +10.2 | +57.4 | +101.6 | +11.0 | +2.8 | +26.1 | +1.6 | +36.2 | -15.0 |
| 2026 | +30.0 | -6.7 | +81.4 | +1.9 | +4.8 | +35.3 | -5.4 | -16.1 | +11.5 |



